Patient disposition. A total of 135 patients enrolled in the study: 120 patients received the initial PK dose of rurioctocog alfa pegol and 115 patients received at least 1 prophylactic dose of rurioctocog alfa pegol. *Patients either completed a previous rurioctocog alfa pegol study (#NCT01599819,¹¹  #NCT01736475,¹¹  #NCT02210091,¹³  #NCT02615691, #NCT01913405,¹²  or #NCT01945593¹⁴ ) or were naive to rurioctocog alfa pegol. †One patient in the screen failure category erroneously received the PK infusion and, although not included in the flowchart, is included in the safety analysis and PK analysis sets.